Changing Policy and Practice in the Control of Pediatric Schistosomiasis
- 1 March 2015
- journal article
- review article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 135 (3) , 536-544
Abstract
Schistosomiasis is a chronic disease that affects ∼200 million people. The extended health impact of the disease has been estimated to exceed that of malaria or tuberculosis and to be nearer to that of HIV/AIDS. Within endemic areas, children carry the heaviest burden of infection. Infection/disease is controlled by the treatment of infected subjects with the anthelminthic drug praziquantel. Global initiatives from Partners of Parasite Control, including the World Health Organization (WHO), advocate regular school-based deworming strategies to reduce the development of severe morbidity, promote school–child health and development, and improve the cognitive potential of children. Until recently, preschool-aged children were excluded from schistosome treatment, creating a health inequity in affected populations. In 2010, the WHO updated their recommendations for the treatment of schistosomiasis in preschool-aged children (ie, children aged ≤5 years). This change was the culmination of several decades of research on schistosome epidemiology, immunology, and pathology in this age group. The recent development of a pediatric formulation of praziquantel (soon to enter clinical trials) should advance control efforts in preschool-aged children, with the goal of including these children in preventative chemotherapy (as currently occurs for soil-transmitted helminths). This review discusses the research work supporting the WHO revision of recommendations for treating preschool-aged children, as well as current barriers and knowledge gaps in pediatric schistosomiasis control.Keywords
This publication has 54 references indexed in Scilit:
- Integrated Analysis of Innate, Th1, Th2, Th17, and Regulatory Cytokines Identifies Changes in Immune Polarisation Following Treatment of Human SchistosomiasisThe Journal of Infectious Diseases, 2012
- Closing the praziquantel treatment gap: new steps in epidemiological monitoring and control of schistosomiasis in African infants and preschool-aged childrenParasitology, 2011
- Exposure, infection, systemic cytokine levels and antibody responses in young children concurrently exposed to schistosomiasis and malariaParasitology, 2011
- Knowledge attitudes and practices of grade three primary schoolchildren in relation to schistosomiasis, soil transmitted helminthiasis and malaria in ZimbabweBMC Infectious Diseases, 2011
- Increases in Levels of Schistosome‐Specific Immunoglobulin E and CD23+B Cells in a Cohort of Kenyan Children Undergoing Repeated Treatment and Reinfection withSchistosoma mansoniThe Journal of Infectious Diseases, 2010
- Urinary schistosomiasis among preschool children in a rural community near Abeokuta, NigeriaParasites & Vectors, 2010
- Schistosomiasis in Africa: An Emerging Tragedy in Our New Global Health DecadePLOS Neglected Tropical Diseases, 2009
- Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western KenyaTropical Medicine & International Health, 2009
- Circulating CD23+B Cell Subset Correlates with the Development of Resistance toSchistosoma mansoniReinfection in Occupationally Exposed Adults Who Have Undergone Multiple TreatmentsThe Journal of Infectious Diseases, 2009
- Taste, A New Incentive to Switch to (R)-Praziquantel in Schistosomiasis TreatmentPLOS Neglected Tropical Diseases, 2009